Is Your Paper Ready for JCO? Practice-Changing Oncology Only

Understanding JCO's publication pattern tells you more than its scope statement does. Here's what fills its pages:

Definitive Phase 3 randomized controlled trials. This is JCO's bread and butter. Large, multicenter, adequately powered Phase 3 trials comparing a new treatment to the established standard of care. The operative word is "definitive." Interim analyses, exploratory subgroup findings, and post-hoc analyses of Phase 3 data occasionally get published, but the core currency is the primary analysis of a completed Phase 3 trial with mature survival data.

Landmark Phase 2 trials for rare cancers. JCO recognizes that Phase 3 trials aren't always feasible for rare malignancies. A well-designed single-arm Phase 2 trial in a cancer that affects a few hundred patients per year can be practice-changing if the response rates are sufficiently dramatic. But the bar here is high: you need to demonstrate that randomization wasn't realistic given the disease rarity, and the treatment effect needs to be large enough that no one could argue equipoise still exists.

Health services research. This category surprises people, but JCO publishes a steady stream of papers on healthcare delivery, outcomes disparities, survivorship, and healthcare economics. The thread connecting these to the clinical mission: they address how oncology care is delivered, not just what treatments work. A paper showing that patients in rural settings have systematically worse access to a proven therapy is practice-changing in the same way a Phase 3 trial is, just at a different level.

Practice guideline-informing meta-analyses and systematic reviews. These need to address a question where clinical practice is genuinely uncertain. A meta-analysis confirming what everyone already knows won't make it through desk review. One that resolves a controversy, say, whether adjuvant therapy benefits a specific molecular subtype, that's a different story.

About one-third of JCO submissions never reach external review. The editors read them, discuss them at their editorial meeting, and send a rejection. Here are the patterns that trigger those fast rejections:

Phase 1 and dose-finding studies. Unless you've found an extraordinary signal in a Phase 1 trial for a previously untreatable cancer, dose-escalation data belongs in specialty journals. JCO isn't interested in pharmacokinetics without clinical endpoints.

Phase 2 trials for common cancers. If there are enough patients to run a Phase 3 trial, JCO expects you to do so. A single-arm Phase 2 trial in non-small cell lung cancer or breast cancer won't get past the desk. There's no rarity argument to justify the absence of randomization.

Biomarker discovery without clinical validation. You've found a biomarker that predicts response in your retrospective cohort. Interesting, but JCO wants prospective validation or at minimum an independent retrospective validation cohort large enough to be convincing. Biomarker papers that stop at "we found an association" belong in Clinical Cancer Research or Cancer Research.

Translational biology with a thin clinical wrapper. Your paper is fundamentally about tumor biology, but you've added a paragraph about how the findings might eventually influence treatment. JCO's editors see through this. If the core contribution is mechanistic rather than clinical, the paper belongs at Cancer Cell, Cancer Discovery, or Nature Cancer.

Surgical technique papers. JCO publishes surgical oncology, but only when the research question is about patient outcomes, not surgical methods. A new laparoscopic approach that reduces operating time won't make it. A randomized trial showing that a particular surgical strategy improves overall survival will.

One thing JCO does well: it doesn't torture you with formatting rules at initial submission. ASCO journals use EZSubmit, a format-free initial submission policy. You don't need to reformat your manuscript to match JCO's style before the first decision.

What you do need to include:

• Cover letter explaining the clinical significance
• Title page with all author information
• Structured abstract
• Complete reference list (any standard format)
• CONSORT flow diagram (if reporting a randomized study)
• Trial protocol (if reporting a randomized or interventional trial)
• Figures and tables (any reasonable format)

What you don't need to worry about: reference formatting, precise word count adherence, specific figure file formats, or font choices. These only matter after provisional acceptance.

The $80 nonrefundable submission fee for Original Reports and Brief Reports is charged at submission. It's not a lot in the context of a clinical trial budget, but it does mean JCO expects you to have done the self-assessment before you submit.

These three journals compete for the same tier of clinical oncology papers, but they have distinct editorial identities:

Choose JCO when your trial will directly change ASCO or NCCN guidelines. If you're running a major Phase 3 trial at US institutions and the result definitively settles a clinical question, JCO is the natural first choice. The ASCO affiliation means your paper will be discussed at ASCO meetings and referenced in ASCO guidelines faster than if it appeared elsewhere.

Choose Lancet Oncology when your trial has a strong international or global health dimension, or when the editorial at Lancet would add a policy perspective your paper benefits from. Lancet Oncology also handles cancer epidemiology papers at a level JCO doesn't prioritize. Lancet's editorial format requires more upfront work, including Lancet-specific formatting from the first submission, but their editorial commentaries (published alongside accepted papers) can amplify your work's impact.

Choose JAMA Oncology when your paper sits at the intersection of clinical oncology and population health, health policy, or healthcare delivery research. JAMA Oncology's scope is broader than JCO's, and it publishes more observational studies and population-based analyses. The impact factor is lower, but the readership among healthcare policymakers may be larger.

A common strategy: submit a definitive Phase 3 trial to JCO first. If desk-rejected (it happens to strong papers when the clinical question isn't high-profile enough), move to Lancet Oncology, then JAMA Oncology. The EZSubmit policy at JCO and JAMA Oncology makes this cascade relatively painless in formatting terms.

If you're reporting a randomized study, CONSORT compliance isn't optional. JCO requires the CONSORT flow diagram showing patient enrollment, randomization, follow-up, and analysis. This isn't a box-checking exercise. Reviewers will check whether your intention-to-treat population matches the CONSORT diagram, whether your per-protocol analysis exclusions are justified, and whether the loss-to-follow-up numbers raise concerns about bias.

For randomized and interventional trials, JCO also requires submission of the trial protocol. Reviewers compare the published paper against the protocol, looking for outcome switching (changing the primary endpoint after the trial started), unregistered subgroup analyses, and deviations from the pre-specified statistical analysis plan. If your paper and your protocol tell different stories, expect hard questions.

Common failure pattern: a CONSORT diagram where half the items say "see Methods section" instead of providing actual numbers. Reviewers interpret this as sloppy trial reporting, and it can sink an otherwise strong paper.

Papers that survive the desk screen get assigned to an Associate Editor and typically two to three external reviewers. The turnaround is fast by clinical journal standards: about four weeks from assignment to decision. JCO's editors know that clinical trial results age poorly. Competing trials may report, treatment landscapes shift, and new standards of care emerge. Speed matters.

First-round decisions at JCO tend to be decisive. You'll get one of three outcomes: accept with minor revisions (rare), major revisions with a clear path to acceptance, or reject after review. The "revise and resubmit with no guarantee" outcome that some journals use is less common at JCO. The editors typically know by the time reviews come back whether the paper will make it.

Revision expectations are focused and clinical. Reviewers will ask about sensitivity analyses, subgroup effects, comparison to other recently reported trials, and clinical applicability. They're less likely to request new experiments (your trial is done, after all) and more likely to request additional statistical analyses, longer follow-up data if available, or clearer discussion of how the findings should change practice.

Run through these before you hit submit:

Is your primary endpoint clinically meaningful? Overall survival remains the gold standard at JCO. Progression-free survival is accepted as a primary endpoint in specific disease settings, but you should be prepared to argue why PFS matters for patient care in your tumor type. Surrogate endpoints like pathologic complete response need context and ideally correlation with survival.

Is your control arm the actual standard of care? If you're comparing your new treatment to a regimen that oncologists stopped using two years ago, the trial result doesn't change practice even if it's positive. JCO editors check this carefully. Your control arm needs to reflect what patients would actually receive today.

Is your sample size adequate for the question? Underpowered trials that claim "no difference" between arms get rejected. So do trials that are powered for an unrealistically large treatment effect. If you assumed a hazard ratio of 0.50 when the realistic expectation was 0.75, your trial may be underpowered, and JCO reviewers will notice.

Have you addressed competing evidence? If another trial on the same question was reported at ASCO last year, your paper needs to address it. JCO editors know the conference data, and they'll wonder why your paper doesn't engage with it.

Is your follow-up mature enough? Reporting overall survival with a median follow-up of 12 months in a disease where median survival is 36 months will raise eyebrows. JCO wants mature data. If your follow-up is too short, consider waiting for the data to mature rather than rushing to publish.

JCO's cover letter is your chance to make the practice-changing argument explicitly. Don't summarize the paper. The editors will read the abstract for that. Instead, answer three questions:

1. What clinical question does this paper answer?
2. What is the current standard of care, and how will your findings change it?
3. Which specific guidelines should be updated based on your results?

If you can't answer the third question with a specific guideline citation, reconsider whether JCO is the right target. Being vague about "potential impact on clinical practice" signals that the practice change isn't clear enough for JCO's scope.

Before submitting to JCO, answer these questions honestly:

Will treatment guidelines change based on your results? Not "might they eventually contribute to a guideline change." Will they change? If you've completed a definitive Phase 3 trial that answers a question the NCCN guidelines panel is waiting on, the answer is yes. If your trial result is one data point among several that might collectively shift opinion, JCO may not be your first choice.

Is your trial design defensible to practicing oncologists? JCO's reviewers are clinicians. They'll evaluate your eligibility criteria, treatment protocols, and endpoints through the lens of clinical practice, not just statistical rigor. Does your trial reflect how patients are actually treated?

Have you presented the data at ASCO or another major meeting? This isn't a requirement, but JCO papers frequently originate from ASCO plenary or oral sessions. If your trial wasn't selected for a major meeting presentation, it may not meet JCO's threshold for clinical significance.

Can you clearly state who should be treated differently based on your results? "Oncologists treating patients with stage III microsatellite-stable colorectal cancer should now consider adding agent X to standard FOLFOX" is the kind of statement JCO papers support. If you can't write a sentence like that, the paper may lack the clinical specificity JCO demands.

A Manusights pre-submission review can evaluate whether your manuscript's framing communicates the practice-changing significance that JCO editors screen for during desk review.